| Title: | Nature-inspired substituted 3-(imidazol-2-yl) morpholines targeting human topoisomerase IIα : dynophore-derived discovery |
|---|
| Authors: | ID Herlah, Barbara (Author)
ID Janežič, Matej (Author)
ID Ogris, Iza (Author)
ID Golič Grdadolnik, Simona (Author)
ID Kološa, Katja (Author)
ID Žabkar, Sonja (Author)
ID Žegura, Bojana (Author)
ID Perdih, Andrej (Author) |
|---|
| Files: |  URL - Source URL, visit https://doi.org/10.1016/j.biopha.2024.116676
 PDF - Presentation file, download (7,99 MB)
MD5: BD6F61C36048CEF603C2D04E9673B6BD
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  KI - National Institute of Chemistry
|
|---|
| Abstract: | The molecular nanomachine, human DNA topoisomerase IIα, plays a crucial role in replication, transcription, and recombination by catalyzing topological changes in the DNA, rendering it an optimal target for cancer chemotherapy. Current clinical topoisomerase II poisons often cause secondary tumors as side effects due to the accumulation of double-strand breaks in the DNA, spurring the development of catalytic inhibitors. Here, we used a dynamic pharmacophore approach to develop catalytic inhibitors targeting the ATP binding site of human DNA topoisomerase IIα. Our screening of a library of nature-inspired compounds led to the discovery of a class of 3-(imidazol-2-yl) morpholines as potent catalytic inhibitors that bind to the ATPase domain. Further experimental and computational studies identified hit compound 17, which exhibited selectivity against the human DNA topoisomerase IIα versus human protein kinases, cytotoxicity against several human cancer cells, and did not induce DNA double-strand breaks, making it distinct from clinical topoisomerase II poisons. This study integrates an innovative natural product-inspired chemistry and successful implementation of a molecular design strategy that incorporates a dynamic component of ligand-target molecular recognition, with comprehensive experimental characterization leading to hit compounds with potential impact on the development of more efficient chemotherapies. |
|---|
| Keywords: | topoisomerase II, catalytic inhibitors, chemotherapy, DNA damage, cancer |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.06.2024 |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 1-18 |
|---|
| Numbering: | Vol. 175, [article no.] 116676 |
|---|
| Source: | Biomedicine & pharmacotherapy |
|---|
| PID: | 20.500.12556/DiRROS-19029  |
|---|
| UDC: | 615.9 |
|---|
| ISSN on article: | 1950-6007 |
|---|
| DOI: | 10.1016/j.biopha.2024.116676 |
|---|
| COBISS.SI-ID: | 196316419 |
|---|
| Copyright: | © 2024 The Authors. |
|---|
| Note: | Soavtorji: Matej Janežič, Iza Ogris, Simona Golič Grdadolnik, Katja Kološa, Sonja Žabkar, Bojana Žegura, Andrej Perdih;
Nasl. z nasl. zaslona;
Opis vira z dne 22. 5. 2024;
|
|---|
| Publication date in DiRROS: | 03.06.2024 |
|---|
| Views: | 592 |
|---|
| Downloads: | 336 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
